Skip to main content
. 2017 May 30;12(5):e0178221. doi: 10.1371/journal.pone.0178221

Fig 1. Combined treatments of CBP-93872 with oxaliplatin, cisplatin, 5-FU, or gemcitabine effectively suppresses cell growth.

Fig 1

(A) HT29 cells were treated with the indicated concentrations of CBP-93872 for 72 hrs, followed by WST-1 assay. Data are presented as means ± SD (n = 3). (B) Panc-1 cells were treated with the indicated concentrations of CBP-93872 for 72 hrs, followed by WST-1 assay. Data are presented as means ± SD (n = 3). (C) HT29 cells were treated with CBP-93872 (50 μM) in combination with indicated concentrations of oxaliplatin, cisplatin or 5-FU for 72 hrs, followed by WST-1 assay. (D) Panc-1 cells were treated with CBP-93872 (200 μM) in combination with indicated concentrations of oxaliplatin, cisplatin or gemcitabine for 72 hrs, followed by WST-1 assay. The black bars show individual treatments; while the white bars show combined treatment with CBP-93872. Data are presented as means ± SD (n = 3). Statistical significance was calculated using Student’s t-test (*, p < 0.01) (C, D).